What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce and provide access to Schering-Plough's (reported under the name Merck & Co., Inc. in the prompt, but the content clearly refers to Schering-Plough) financial results for the fourth quarter and full year of 2005. It also serves to furnish the official press release and supplemental financial data related to these results.

Where can I find the specific financial numbers for the 4th quarter and full year 2005?

The specific financial results, including detailed figures for the fourth quarter and full year 2005, are not directly included in the text of the 8-K filing itself. Investors need to refer to the furnished exhibits: Exhibit 99.1 (Press Release) and Exhibit 99.2 (Supplemental Financial Data), which contain this detailed financial information.

What are the major risks and uncertainties mentioned in the filing that could affect Merck's (Schering-Plough's) future performance?

The filing highlights several key risks, including heavy reliance on specific products like the cholesterol franchise, uncertainties in pharmaceutical product development and regulatory approvals, potential post-market safety issues, intense competition, pricing pressures, regulatory compliance challenges (including an FDA consent decree), potential adverse outcomes in legal proceedings, patent disputes, tax law changes, and general economic factors.

Does this filing provide updated guidance or outlook for 2006?

While the filing contains a significant section on 'Forward Looking Statements' that discusses future expectations and potential scenarios, it does not provide explicit quantitative guidance for 2006 within the provided text. Investors should look for specific forward-looking statements within the furnished press release (Exhibit 99.1) and supplemental data (Exhibit 99.2) for any updated outlook.

MRK 8-K: Earnings & Results

Summary

This 8-K filing from Merck & Co., Inc. (filed under the name Schering-Plough in this document, indicating a potential reporting error or historical context where Merck may have been involved with Schering-Plough through a partnership or acquisition) reports the financial results for the fourth quarter and full year of 2005. The primary focus is on the release of the earnings press release and supplemental financial data as exhibits. While the filing doesn't provide specific financial figures within the 8-K text itself, it directs investors to detailed information in the furnished exhibits (99.1 and 99.2). The filing also includes a significant 'Disclosure Notice for Forward Looking Statements,' outlining numerous risks and uncertainties that could affect the company's future performance. Investors should pay close attention to these forward-looking statements and the potential risks highlighted, as they provide crucial context for understanding the company's operational environment and potential challenges.

Key Highlights

1Merck & Co., Inc. (reported as Schering-Plough) filed an 8-K on January 30, 2006, to report 2005 fourth quarter and full-year financial results.
2The key information is contained within furnished exhibits: a press release (Exhibit 99.1) and supplemental financial data (Exhibit 99.2).
3The filing emphasizes a 'Disclosure Notice for Forward Looking Statements,' alerting investors to potential future uncertainties.
4Key risk factors discussed include dependence on specific product franchises (e.g., cholesterol), uncertainties in product development and regulatory approvals, post-market product concerns, competition, and pricing pressures.
5The company also highlights risks related to regulatory compliance (including ongoing FDA consent decree provisions), legal proceedings, patent disputes, tax law changes, and economic fluctuations.
6Investor attention is directed to the detailed financial performance and forward-looking statements within the referenced exhibits for a comprehensive understanding of the company's financial condition and operational outlook for 2005 and beyond.

Merck & Co., Inc. 8-K Report, Financial Results (Jan 30, 2006)

Summary

Key Highlights

Frequently Asked Questions